Aspirin dose, urinary thromboxane and prostacyclin metabolites, and clinical outcome in acute coronary syndrome: A nested case-control study from CURRENT-OASIS 7
{{output}}
Background: Aspirin reduces urinary thromboxane, which predicts major adverse cardiovascular events (MACE) during aspirin therapy. However, in CURRENT-OASIS 7, higher-dose aspirin did not improve outcomes compared with lower-dose... ...
